Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.
Australian stem cell company Genea Biocells is expanding its operations to the US with the opening of a new facility in San Diego, California. The office and laboratory space in the Torrey Pines Science Park will accommodate the company's cell and culture media manufacturing, research services, and R&D, and is expected to be fully operational by September 2015.
The new site will house over $2 million worth of equipment, including robotics and instrumentation for high-throughput/high-content screening, all of which is instrumental to the company's chemical biology approach and the research services it provides. Genea Biocells' vice-presidents of chemistry and of business development are already based in the US; the company will retain a small team of scientists in Sydney, primarily for the derivation and banking of new human pluripotent stem cell lines.
"The new facility not only places us directly into our main market, the USA, but also in the midst of one of the largest biotechnology clusters in the world," Genea Biocells general manager, Uli Schmidt, said in a press release. "Being in California also offers a new range of funding opportunities that we will explore to support our R&D programs on neuromuscular diseases."
Source: Genea
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.